22 citations
,
May 2017 in “Journal of dermatological treatment” BD 1/4 dilution is the best for treating localized alopecia areata in adults.
7 citations
,
December 2022 in “Skin Appendage Disorders” Certolizumab effectively treats psoriasis and psoriatic arthritis with fewer side effects than adalimumab.
24 citations
,
May 2015 in “Schizophrenia Research” A drug improved schizophrenia-like symptoms in stressed rats by changing brain steroid levels.
1 citations
,
April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.
August 2024 in “Food Bioscience” Bifidobacterium longum BB536 metabolites may help treat hair loss by repairing and promoting hair cell growth.
October 2024 in “Canadian Journal of Health Technologies” Olumiant should be covered for severe alopecia areata if certain conditions are met.
July 2013 in “Our Dermatology Online” Oral methylprednisolone pulse therapy helped an 11-year-old regrow 80% of his hair in six months.
1 citations
,
November 2007 in “Neuro-chirurgie/Neurochirurgie” Cyproterone acetate is a safe treatment that causes modest feminization in transgender female adolescents, and works better with added estrogens.
1 citations
,
August 2024 in “GeroScience” 1 citations
,
November 2021 in “British Journal of Clinical Pharmacology” Saw palmetto may cause erectile dysfunction and needs better safety monitoring.
November 2023 in “SKIN The Journal of Cutaneous Medicine”
April 2023 in “Tikrit Journal of Pharmaceutical Sciences” Deferasirox effectively reduces iron overload in ß-thalassemia patients but may cause some manageable side effects.
February 2017 in “The Journal of Sexual Medicine” Long-term testosterone treatment helps men with low testosterone levels lose weight.
March 2026 in “Frontiers in Bioscience-Elite” Duloxetine, escitalopram, and finasteride may be effective against bacteria and fungi.
10 citations
,
November 2017 in “Letters in drug design & discovery” Researchers identified promising inhibitors for the BRD4 protein, including finasteride and amentoflavone.
22 citations
,
September 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.
September 2023 in “PubMed” Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
11 citations
,
November 2011 in “Neuroreport” Paroxetine relieves pain by increasing allopregnanolone levels.
3 citations
,
October 2021 in “Brain Sciences” Long-term use of Risperidone may be linked to a serious skin condition in bipolar patients, affecting their overall well-being.
12 citations
,
August 2020 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Azathioprine is the most continued treatment for chronic alopecia areata over a year, often with added low-dose prednisolone.
February 2025 in “Canadian Journal of Health Technologies” Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.
August 2001 in “Journal of Cutaneous Medicine and Surgery” Prednisone has risks for lupus patients, isotretinoin is safe for mental health, transplant patients risk skin cancer, and various treatments are effective for specific skin conditions.
CD28 is a promising target for treating alopecia areata with belatacept.
CD28 is a promising target for treating alopecia areata with belatacept.
July 2000 in “Hair transplant forum international”
October 2024 in “Intisari Sains Medis” Combining secretome with other treatments quickly improves eyebrow hair growth in alopecia areata.
September 2021 in “Medicina estética” Sabal serrulata and biomimetic peptides with microneedling reduced hair loss and improved hair thickness in men with balding.
January 2018 in “Journal of the American Academy of Dermatology” More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.
October 2023 in “Regular and Young Investigator Award Abstracts” Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.
November 2023 in “Journal of Cosmetic Dermatology” Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.